Librexia-AF

Objective

A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation.

Research Study Categories

• Adult Research Studies

Specialties

• Cardiology

Contact

Cardiology Clinical Trials at 866-839-4128, [email protected]